Last reviewed · How we verify
Paracetamol formulation 1
At a glance
| Generic name | Paracetamol formulation 1 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (PHASE1, PHASE2)
- NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL) (PHASE4)
- HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (PHASE2)
- Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery (PHASE3)
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants (PHASE1)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
- Oral Versus Intravenous Acetaminophen for Postoperative Pain Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paracetamol formulation 1 CI brief — competitive landscape report
- Paracetamol formulation 1 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI